dietworks glp-1 companion semaglutide support Ozempic, Wegovy inspire wave of supplements—but are they safe or effective? Nature Made GLP-1 Companion Health

Results: The 18-month risk for ION was 8.5 versus 5.5 per 10 000 among GLP-1RA users versus SGLT2i users (RD, 3.0 [95% CI, 0.4 to 5.7]) and 7.8 versus 4.2 per 10 000 among GLP-1RA users versus DPP4i users (RD, 3.6 [CI, 1.1 to 6.1])

(2019) 11:e6355

J., Vico, M

This includes using sunscreen with an SPF of 30 or higher, as UV exposure can cause new melanin production, diminishing the treatments effects

Zepbounds dual-agonist nature, activating both GLP-1 and GIP receptors, gives it an added advantage in suppressing appetite and aiding insulin secretion more effectively than Wegovy, which only targets the GLP-1 pathway